The core gene RHOA and hub ECD-associated lncRNAs AL157935.2, AC009495.1, and TFAP2A-AS1 have the potential to serve as biomarkers for the prognosis of CM patients and reflect their immune conditions. This evidence concerns the gene TFAP2A and cutaneous mastocytosis.